STRO Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -436.62% compared to Sutro Biopharma's net margin of --. Sutro Biopharma's return on equity of -322.47% beat Perspective Therapeutics's return on equity of --.

Sutro Biopharma has a consensus price target of $3.29, signalling upside risk potential of 303.11%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 453.22%. Given that Perspective Therapeutics has higher upside potential than Sutro Biopharma, analysts believe Perspective Therapeutics is more attractive than Sutro Biopharma.

Sutro Biopharma has a beta of 1.775, which suggesting that the stock is 77.488% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Sutro Biopharma quarterly revenues are $17.4M, which are larger than Perspective Therapeutics quarterly revenues of --. Sutro Biopharma's net income of -$76M is lower than Perspective Therapeutics's net income of -$40.2M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 1.01x versus 16.51x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Mersana Therapeutics has a net margin of -436.62% compared to Sutro Biopharma's net margin of -86.29%. Sutro Biopharma's return on equity of -322.47% beat Mersana Therapeutics's return on equity of -533.43%.

Sutro Biopharma has a consensus price target of $3.29, signalling upside risk potential of 303.11%. On the other hand Mersana Therapeutics has an analysts' consensus of $4.57 which suggests that it could grow by 1176.22%. Given that Mersana Therapeutics has higher upside potential than Sutro Biopharma, analysts believe Mersana Therapeutics is more attractive than Sutro Biopharma.

Sutro Biopharma has a beta of 1.775, which suggesting that the stock is 77.488% more volatile than S&P 500. In comparison Mersana Therapeutics has a beta of 1.319, suggesting its more volatile than the S&P 500 by 31.945%.

Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mersana Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. Mersana Therapeutics pays out -- of its earnings as a dividend.

Sutro Biopharma quarterly revenues are $17.4M, which are larger than Mersana Therapeutics quarterly revenues of $16.4M. Sutro Biopharma's net income of -$76M is lower than Mersana Therapeutics's net income of -$14.1M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Mersana Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 1.01x versus 1.08x for Mersana Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -436.62% compared to Sutro Biopharma's net margin of 26.7%. Sutro Biopharma's return on equity of -322.47% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Sutro Biopharma has a consensus price target of $3.29, signalling upside risk potential of 303.11%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $793.05 which suggests that it could grow by 38.12%. Given that Sutro Biopharma has higher upside potential than Regeneron Pharmaceuticals, analysts believe Sutro Biopharma is more attractive than Regeneron Pharmaceuticals.

Sutro Biopharma has a beta of 1.775, which suggesting that the stock is 77.488% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. Sutro Biopharma pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Sutro Biopharma quarterly revenues are $17.4M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Sutro Biopharma's net income of -$76M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 1.01x versus 4.65x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Voyager Therapeutics has a net margin of -436.62% compared to Sutro Biopharma's net margin of -479.24%. Sutro Biopharma's return on equity of -322.47% beat Voyager Therapeutics's return on equity of -26.82%.

Sutro Biopharma has a consensus price target of $3.29, signalling upside risk potential of 303.11%. On the other hand Voyager Therapeutics has an analysts' consensus of $16.00 which suggests that it could grow by 381.03%. Given that Voyager Therapeutics has higher upside potential than Sutro Biopharma, analysts believe Voyager Therapeutics is more attractive than Sutro Biopharma.

Sutro Biopharma has a beta of 1.775, which suggesting that the stock is 77.488% more volatile than S&P 500. In comparison Voyager Therapeutics has a beta of 0.950, suggesting its less volatile than the S&P 500 by 5.041%.

Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Voyager Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. Voyager Therapeutics pays out -- of its earnings as a dividend.

Sutro Biopharma quarterly revenues are $17.4M, which are larger than Voyager Therapeutics quarterly revenues of $6.5M. Sutro Biopharma's net income of -$76M is lower than Voyager Therapeutics's net income of -$31M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Voyager Therapeutics's PE ratio is 6.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 1.01x versus 2.84x for Voyager Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.